Pl-3K/Akt/GSK-3β signaling cascades stimulated by insulin like growth factor-I contribute to multiple myeloma cells proliferation and survival

Chinese Medical Journal

Volumn 119, Issue 14, 2006, Pages 1226-1229

  Wang, Meng Chang ^a   Fu, Xue De ^b   Li, Man Xiang ^b  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Insulin like growth factor I; Multiple myeloma; PI 3K

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SOMATOMEDIN C; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; INTERLEUKIN 6;

APOPTOSIS; ARTICLE; CANCER CELL; CELL ASSAY; CELL PROLIFERATION; CELL STIMULATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; SIGNAL TRANSDUCTION; WESTERN BLOTTING; DRUG EFFECT; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INTERLEUKIN-6; MULTIPLE MYELOMA; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 33746328095     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200607020-00018     Document Type: Article

References (14)

1. Hilbert D, Kopf M, Mock B, Kohler G, Rudikoff S. Interleukin 6 is essential for in vivo development of B lineage neoplasms. J Exp Med 1995;182:243-248.
2. Lattanzio G, Libert C, Aquilina M, Cappelletti M, Ciliberto G, Musiani P, et al. Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice. Am J Pathol 1997;151:689-696.
3. Anderson KC, Jones RM, Morimoto C, Leavitt P, Barut BA. Response patterns of purified myeloma cells to hematopoietic growth factors. Blood 1989;73:1915-1924.
4. Alexia C, Fourmatgeat P, Delautier D, Groyer A. Insulin-like growth factor-I stimulates H(4)II rat hepatoma cell proliferation: Dominant role of PI-3′K/Akt signaling. Exp Cell Res 2006;312:1142-1152.
5. Ge NL, Rudikoff S. Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood 2000; 96:2856-2861.
6. Ferlin M, Noraz N, Hertogh C, Brochier J, Taylor N, Klein B. Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway. Br J Haematol 2000;111:626-634.
7. Jelinek DF, Witzig TE, Arendt BK. A role for insulin-like growth factor in the regulation of IL-6 responsive human myeloma cell line growth. J Immunol 1997;159:487-496.
8. Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004;9:667-676.
9. Radeff-Huang J, Seasholtz TM, Matteo RG, Brown JH. G protein mediated signaling pathways in lysophospholipid induced cell proliferation and survival. J Cell Biochem 2004; 92: 949-966.
10. Porter AC, Vaillancourt RR. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene 1998;17:1343-1352.
11. Pap M, Cooper GM. Role of translation initiation factor 2B in control of cell survival by the phospatidylinositol 3-kinase/Akt/glycogen synthase kinase 3 beta signaling pathway. Mol Cell Boil 2002; 22:578-586.
12. Li M, Wang X, Meintzer MK, Laessig T, Bimbaum MJ, Heidenreich KA. Cyclic AMP promotes neuronal survival by phosphorylation of glycogen synthase kinase 3 beta. Mol Cell Biol 2000;20:9356-9363.
13. Murphy E. Inhibit GSK-3 beta or there is heartbreak dead ahead. J Clin Invest 2004;113:1526-1528.
14. van Zaanen HC, Lokhorst HM, Aarden LA, Rensink HJ, Wamaar SO, van der Lelie J, et al. Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study. Br J Haematol 1998;102:783-790.